Clinical Trials | December 30, 2025
Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Subscribe To Our Newsletter & Stay Updated
